Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo.

Abstract

Colorectal cancer is one of the most common causes of cancer-related death in humans. Coptisine (COP) is a natural alkaloid from Coptidis Rhizoma with unclear antitumor mechanism. Human colon cancer cells (HCT-116) and xenograft mice were used to systematically explore the anti-tumor activity of COP in this study. The results indicated that COP exhibited remarkably cytotoxic activities against the HCT-116 cells by inducing G1-phase cell cycle arrest and increasing apoptosis, and preferentially inhibited the survival pathway and induced the activation of caspase proteases family of HCT-116 cells. Experimental results on male BALB/c nude mice confirmed that orally administration of COP at high-dose (150 mg/kg) could suppress tumor growth, and may reduce cancer metastasis risk by inhibiting the RAS-ERK pathway in vivo. Taken together, the results suggested that COP may be potential as a novel anti-tumor candidate in the HCT-116 cells-related colon cancer, further studies are still needed to suggest COP for the further use.

• Authors: Tao Huang, Yubo Xiao, Lin Yi, Ling Li, Meimei Wang, Cheng Tian, Hang Ma, Kai He, Yue Wang, Bing Han, Xiaoli Ye, Xuegang Li
• Journal: Scientific reports (Sci Rep) Vol. 7 Pg. 38524 (02 06 2017) ISSN: 2045-2322 [Electronic] England
• PMID: 28165459 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• coptisine
• Berberine

Topics

• Administration, Oral
• Animals
• Antineoplastic Agents (administration & dosage, isolation & purification, pharmacology)
• Araceae (chemistry)
• Berberine (administration & dosage, analogs & derivatives, isolation & purification, pharmacology)
• Cell Proliferation (drug effects)
• Colorectal Neoplasms (drug therapy, pathology)
• Disease Models, Animal
• HCT116 Cells (drug effects)
• Heterografts
• Humans
• Mice, Inbred BALB C
• Mice, Nude
• Neoplasm Transplantation
• Treatment Outcome